Abstract
The acute phase response is a major pathophysiologic phenomenon that accompanies inflammation whether acute or chronic. Complement (C3 and C4) and C - reactive protein (CRP) are positive acute phase proteins (+ ve APPs ). Their production takes place in hepatocyte and the blood concentration of these parameters are increased in osteoarthritis (OA). Chloroquine (CQ) is a diprotic weak base traditionally used to treat malaria. Recently the phosphate salt of CQ is used to decrease this type of (+ve APPs) . In this study, patients who suffered from knee osteoarthritis (KOA) are treated with oral dosage form of chloroquine phosphate (CQP) for one month, twice daily. Our results demonstrate that CQP improves the patient status by decreasing complement and C-reactive protein in blood.
 Key words: Chloroquine , knee osteoarthritis , acute phase proteins , complement , C-reactive protein.
Highlights
OA is the most common disease in the world and a major cause of pain and disability which usually develops in distal inter phalangeal (DIP )joints of finger, the weight bearing joints of leg and the movable portion of spine[1]
chloroquine phosphate (CQP) is used by some authors in the OA as disease modifying anti –rheumatic drug ( DMARD) [4], claimed to cause lowering of blood level of proinflammatory mediators [5]
Our study shows the effect of CQP on the serum concentration of C - reactive protein (CRP), C3 and C4 in patients with knee osteoarthritis (KOA).C-reactive protein is a laboratory marker that is important in the assessment of inflammation, serve as a predictor and indicator of response to therapy and overall outcome in various disorders [6]
Summary
OA is the most common disease in the world and a major cause of pain and disability which usually develops in distal inter phalangeal (DIP )joints of finger, the weight bearing joints of leg and the movable portion of spine[1]. CQP is used by some authors in the OA as disease modifying anti –rheumatic drug ( DMARD) [4], claimed to cause lowering of blood level of proinflammatory mediators [5] .
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Iraqi Journal of Pharmaceutical Sciences ( P-ISSN: 1683 - 3597 , E-ISSN : 2521 - 3512)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
